{
  "id": 205224,
  "name": "ALEXION PHARMACEUTICALS, INC.",
  "slug": "alexion-pharmaceuticals-inc",
  "state": "MA",
  "description": "Biopharmaceutical Company.",
  "totalSpending": 1970000,
  "filings": 26,
  "yearlySpending": [
    {
      "year": 2020,
      "income": 180000
    },
    {
      "year": 2021,
      "income": 390000
    },
    {
      "year": 2022,
      "income": 480000
    },
    {
      "year": 2023,
      "income": 280000
    },
    {
      "year": 2024,
      "income": 400000
    },
    {
      "year": 2025,
      "income": 240000
    }
  ],
  "firms": [
    "TODD STRATEGY GROUP"
  ],
  "lobbyists": [
    "DANIEL TODD",
    "PAUL EDATTEL",
    "JEFF LUCAS",
    "NICHOLAS UEHLECKE",
    "ERIC BERGREN",
    "KATHERINE COTTON",
    "TED LEHMAN",
    "TAYLOR SEXTON",
    "KIMBERLY LINTHICUM"
  ],
  "issues": [
    "HCR",
    "MMM",
    "LBR",
    null
  ],
  "sampleDescriptions": [
    "Home Infusion.\nCOVID-19 Response.",
    "COVID-19 Response.",
    "Home Infusion.\nPatient-Centered Outcomes Research Institute Nominations.",
    "Home Infusion.\nMedicare Reimbursement for New Technologies.",
    "Rare disease designation.\nH.R.5376 - Build Back Better Act.\nH.R.3684 - Infrastructure Investment and Jobs Act.",
    "Medicare Reimbursement for New Technologies.",
    "Employee Retirement Income Security Act (ERISA) issues.",
    "Medicare Reimbursement for New Technologies. 340B. Home Infusion for Part B Products. H.R.830 - HELP Copays Act.",
    "General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection.",
    "340B. Home Infusion for Part B Products. H.R.830 - HELP Copays Act.",
    "General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.",
    "340B Program. Home Infusion for Part B Products. H.R.830 - HELP Copays Act. Medicare Reimbursement for New Technologies.",
    "340B Program. Home Infusion for Part B Products. S.864 - HELP Copays Act. Medicare Reimbursement for New Technologies.",
    "General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act."
  ],
  "years": [
    2020,
    2021,
    2022,
    2023,
    2024,
    2025
  ],
  "growthRate": 33,
  "trajectory": "growing",
  "yearsActive": 6,
  "avgAnnualSpending": 328333,
  "peakYear": 2022,
  "lobbyistCount": 9,
  "firmCount": 1,
  "issueCount": 3,
  "industry": "healthcare"
}